title: Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain.
abstract: Three pups 2-4 months old were vaccinated subcutaneously with the modified live canine parvovirus, CPV-2b/29-97 strain. During an observation period of two weeks pups remained clinically health, exhibiting a vigorous post-vaccinal active serological response (haemoagglutinating inhibiting antibody titers for CPV-2 ranging from 1:2560 to 1:5120 at 21 days post inoculation). Phagocytosis and killing of Candida albicans exerted by polymorphonuclear cells and monocytes did not undergo significant modifications 3-6 days post vaccination up to 30 days. Antibacterial activity mediated by peripheral blood lymphocytes (Salmonella typhi was used as a target) was slightly, but not significantly decreased 3 days post vaccination. Conclusively, in pups the CPV type 2b vaccine seems to be safe as far as natural immune responses are concerned, while its immunogenicity is preserved.
authors.affiliation: Department of Health and Animal Welfare, Faculty of Veterinary Medicine, University of Bari, Valenzano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Pratelli
authors.forename: M
authors.initials: M
authors.lastname: Altamura
authors.forename: D
authors.initials: D
authors.lastname: Buonavoglia
authors.forename: M
authors.initials: M
authors.lastname: Pepe
authors.forename: A
authors.initials: A
authors.lastname: Tafaro
authors.forename: A
authors.initials: A
authors.lastname: Lembo
authors.forename: F
authors.initials: F
authors.lastname: Cirone
authors.forename: M
authors.initials: M
authors.lastname: Tempesta
authors.forename: E
authors.initials: E
authors.lastname: Jirillo
authors.forename: C
authors.initials: C
authors.lastname: Buonavoglia
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001770:Blood Bactericidal Activity; D002176:Candida albicans / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control; D004285:Dogs; D007113:Immunity, Innate; D066298:In Vitro Techniques; D007279:Injections, Subcutaneous; D009000:Monocytes / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D010322:Parvoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary; D017993:Parvovirus, Canine / Q000145:classification / Q000276:immunology*; D010587:Phagocytosis; D012449:Safety; D012485:Salmonella typhi / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000914:Antibodies, Viral; D014765:Viral Vaccines